Document Detail

Comparison of the selection of antimicrobial resistance in fecal Escherichia coli during enrofloxacin administration with a local drug delivery system or with intramuscular injections in a swine model.
MedLine Citation:
PMID:  18783019     Owner:  NLM     Status:  MEDLINE    
This study evaluated, for the first time, the selection of antibiotic resistance in fecal Escherichia coli, a potential reservoir of genes of resistance, during the prolonged exposure to fluoroquinolones after the implantation of a local drug delivery system (LDDS) in a swine model. Fourteen pigs were randomly assigned to group IM (5 mg/kg/day of intramuscular enrofloxacin--EFX) or LD (surgical implantation of EFX-polymethyl-methacrylate peri-femoral implants). Blood samples were collected daily for determination of plasma EFX and ciprofloxacin (CFX) concentrations. Fecal samples were collected daily to determine the E. coli counts and the susceptibility patterns of its isolates as evaluated by antibiotic disk diffusion tests. In both groups, EFX administration significantly reduced the bacterial counts after 2 days. During recolonization, the bacterial counts remained lower than baseline in group IM but not significantly, and almost reached pre-treatment levels in group LD. Susceptibility to EFX, CFX, and nalidixic acid of recolonizing E. coli in LD pigs slightly decreased but remained within the limit of "susceptible" isolates. In contrast, quinolone susceptibility of recolonizing E. coli in IM pigs dropped dramatically (P < 0.0001). In addition, intramuscular exposure to fluoroquinolones significantly decreased the susceptibility of E. coli to ampicillin and trimethoprim-sulfamethoxazole (P < 0.05). In conclusion, the use of a dosing regimen that minimized the intestinal output of fluoroquinolones also minimized the selection of resistance to several classes of antibiotics. This could represent another advantage of LDDS usage compared to long-lasting systemic administration of fluoroquinolones.
Romain Béraud; Louis Huneault; Dave Bernier; Francis Beaudry; Ann Letellier; Jérôme R E del Castillo
Related Documents :
24212359 - The application of digital volume correlation (dvc) to study the microstructural behavi...
12205059 - Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on ex...
16227349 - Vibrionaceae as a possible source of qnr-like quinolone resistance determinants.
20385869 - Recombinant phenotyping of cytomegalovirus ul97 kinase sequence variants for ganciclovi...
12499219 - Gyra mutations in ciprofloxacin-resistant bartonella bacilliformis strains obtained in ...
9125039 - Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance a...
23605899 - Do the pigments differ chemotaxonomically fungi belonging to genusfusarium?
20844809 - Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in saudi ...
20828469 - Thermal inactivation of heat-shocked escherichia coli o157:h7, salmonella, and listeria...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Canadian journal of veterinary research = Revue canadienne de recherche vétérinaire     Volume:  72     ISSN:  0830-9000     ISO Abbreviation:  Can. J. Vet. Res.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-09-11     Completed Date:  2008-10-20     Revised Date:  2010-09-22    
Medline Journal Info:
Nlm Unique ID:  8607793     Medline TA:  Can J Vet Res     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  311-9     Citation Subset:  IM    
Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / therapeutic use*
Disease Reservoirs / veterinary
Drug Implants
Drug Resistance, Bacterial*
Escherichia coli / drug effects*,  genetics,  growth & development
Escherichia coli Infections / drug therapy,  microbiology,  veterinary*
Feces / microbiology*
Fluoroquinolones / administration & dosage,  therapeutic use*
Injections, Intramuscular / veterinary
Microbial Sensitivity Tests / veterinary
Random Allocation
Selection, Genetic
Swine Diseases / drug therapy*,  microbiology
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Drug Implants; 0/Fluoroquinolones; 93106-60-6/enrofloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pig and herd level prevalence of Toxoplasma gondii in Ontario finisher pigs in 2001, 2003, and 2004.
Next Document:  PrP genotype frequencies of Quebec sheep breeds determined by real-time PCR and molecular beacons.